You are viewing: South Korea Hemostats Market analysis
Part of: Hemostats Market (Global)

The South Korea Hemostats Market was valued at $13 Million in 2025 and projected to reach to $20.6 Million by 2030, representing a compound annual growth rate of 9.6%. South Korea's hemostats market is positioned for sustained expansion through 2030, driven by an aging population requiring increased surgical interventions and a healthcare system prioritizing advanced treatment modalities.

South Korea Hemostats Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Hemostats Market Trends and Insights

  • This 9.6% compound annual growth rate significantly outpaces global trends, reflecting South Korea's advanced healthcare infrastructure and rising surgical volumes.
  • South Korea's aging population and increasing prevalence of chronic conditions are driving demand for effective hemostatic solutions across hospitals and surgical centers. The South Korea hemostats market benefits from strong healthcare spending, technological innovation, and a well-established medical device ecosystem.
  • South Korea's regulatory environment supports rapid adoption of advanced hemostatic products, including topical agents, mechanical devices, and combination therapies.
  • Between 2025 and 2030, South Korea is expected to see accelerated market penetration driven by minimally invasive surgical procedures and enhanced clinical awareness among healthcare providers..

Key Market Statistics

  • CAGR (2025-2030) 9.6% CAGR
  • Market Size, 2025 ~USD 13 Million
  • Forecast, 2030 ~USD 20.6 Million
  • Country South Korea

South Korea Hemostats Market Overview

Outpacing Global Growth :

South Korea's hemostats market grows at 9.6% CAGR, significantly exceeding the global rate of 6.4%, driven by advanced surgical capabilities and healthcare investment.

Aging Population Dynamics :

South Korea's rapidly aging demographic is increasing surgical procedures and chronic disease management, creating sustained demand for hemostatic solutions across hospitals and surgical centers.

Advanced Healthcare Infrastructure :

South Korea's state-of-the-art medical facilities and high adoption of innovative surgical technologies position it as a premium market for advanced hemostat products.

Market Expansion Trajectory :

Valued at $13.0 million in 2025, the market is projected to reach $20.6 million by 2030, representing a 58% increase over five years.

South Korea Hemostats Market Dynamics

  • The country's strong economic foundation and healthcare spending support adoption of premium hemostatic products across surgical specialties.
  • Rising prevalence of cardiovascular and orthopedic conditions will further accelerate market growth. Key growth catalysts include expanding surgical volumes in tertiary care centers, increasing minimally invasive procedure adoption, and growing healthcare provider investment in bleeding management solutions.
  • South Korea's regulatory environment and strong reimbursement framework create favorable conditions for market entrants.
  • Continued innovation in hemostatic technology and strategic partnerships with local healthcare providers will be critical to capturing market share in this high-growth segment..

Related Ecosystem

Medical Devices

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Magnetic Resonance Imaging (MRI)
  • Disposable Autoinjectors
  • Pulse Oximeters
  • Blood Pressure Monitors
Top Companies
  • Medtronic plc
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson and Company
  • JOHNSON & JOHNSON

    Key Takeaways

    • South Korea's hemostats market is valued at $13.0 million in 2025 and will reach $20.6 million by 2030, growing at 9.6% CAGR.
    • South Korea's advanced healthcare infrastructure and aging demographics are primary drivers of hemostats market expansion.
    • South Korea's regulatory environment accelerates adoption of innovative hemostatic technologies and combination products.
    • Minimally invasive surgical procedures in South Korea are creating sustained demand for advanced hemostatic solutions through 2030.

    Hemostats Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment RECONSTRUCTIVE SURGERY (Application)
    Forecast Period 2025–2030
    Growth Rate CAGR of 6.4% from 2025 to 2030
    Largest Segment HOSPITALS (End User)
    Market Size Base Year (Billions) ~USD 2.93 (2025)
    Revenue Forecast (Billions) ~USD 4 (2030)
    Segments Covered Type, Formulation, Application, End User

    South Korea Hemostats Market Report Segmentation

    4 segment dimensions are covered across the global market.

    By Type

    • Collagen-Based Hemostats
    • Combination Hemostats
    • Gelatin-Based Hemostats
    • Other Types
    • Oxidized Regenerated Cellulose-Based Hemostats
    • Thrombin-Based Hemostats

    By Formulation

    • Matrix & Gel Hemostats
    • Powder Hemostats
    • Sheet & Pad Hemostats
    • Sponge Hemostats

    By Application

    • Cardiovascular Surgery
    • General Surgery
    • Gynecological Surgery
    • Neurological Surgery
    • Orthopedic Surgery
    • Other Surgeries
    • Reconstructive Surgery

    By End User

    • Hospitals
    • Specialty Clinics

    Target Audience

    • Medical Device Manufacturers : Evaluate South Korea as a strategic market for hemostats product launches, expansion, and portfolio optimization with clear growth projections and market sizing data.
    • Healthcare Investors & PE Firms : Assess investment opportunities in South Korea's high-growth hemostats sector with quantified market potential, demographic tailwinds, and competitive landscape insights.
    • Hospital & Surgical Center Operators : Understand market trends and procurement opportunities for hemostatic products to optimize surgical supply chains and improve patient outcomes in South Korea.
    • Market Entry & Strategy Consultants : Support client advisory with South Korea-specific market intelligence, competitive positioning, and growth strategy recommendations for hemostats market participants.
    • Healthcare Policy & Regulatory Bodies : Inform policy decisions and regulatory frameworks with comprehensive market data on South Korea's hemostats sector growth, innovation trends, and healthcare needs.

    Key Companies in the South Korea Hemostats Market

    CompanyHQOwnershipStrongest segments
    CSL LIMITEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BAXTERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    PFIZER INC.United StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    BECTON, DICKINSON AND COMPANY (BD)United States
    TELEFLEX INCORPORATEDUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    MEDTRONIC PLCIrelandPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    STRYKERUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    INTEGRA LIFESCIENCESUnited StatesPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,
    ADVANCED MEDICAL SOLUTIONS GROUP PLCUnited KingdomPublic CompanyGelatin-based hemostats,Collagen-based hemostats,Combination hemostats and biosurgical adjuncts,
    SAMYANG CORPORATIONKorea, Republic ofPublic CompanyThrombin Hemostats,Combination Hemostats,Gelatin Hemostats,

    CSL LIMITED

    CSL LIMITED is a public company founded in 1916 and headquartered in the United States, employing 29,904 people. The company operates in the biotechnology and pharmaceutical sectors.

    BAXTER

    BAXTER is a public company founded in 1931 in the United States, employing 37,500 people. The company operates in the medical devices and pharmaceutical sectors.

    PFIZER INC.

    PFIZER INC. is a public company founded in 1950 in the United States with 1,244 employees. The company operates in the pharmaceutical and healthcare industry.

    BECTON, DICKINSON AND COMPANY (BD)

    BECTON, DICKINSON AND COMPANY (BD) is a company headquartered in the United States. The company operates in the medical devices and healthcare sectors.

    TELEFLEX INCORPORATED

    TELEFLEX INCORPORATED is a public company founded in 1943 in the United States, employing 15,500 people. The company manufactures medical devices and specialty healthcare products.

    MEDTRONIC PLC

    MEDTRONIC PLC is a public company founded in 1949 and headquartered in Ireland, employing 95,000 people. The company is a global leader in medical technology and healthcare solutions.

    STRYKER

    STRYKER is a public company founded in 1941 in the United States, employing 56,000 people. The company is a leading manufacturer of medical devices and surgical equipment.

    INTEGRA LIFESCIENCES

    INTEGRA LIFESCIENCES is a public company founded in 1989 in the United States, employing 4,427 people. The company develops and manufactures medical devices and regenerative medicine products.

    ADVANCED MEDICAL SOLUTIONS GROUP PLC

    ADVANCED MEDICAL SOLUTIONS GROUP PLC is a public company founded in 1991 in the United Kingdom, employing 1,800 people. The company specializes in advanced wound care and medical device solutions.

    SAMYANG CORPORATION

    SAMYANG CORPORATION is a public company founded in 1961 in the Republic of Korea, employing 1,994 people. The company operates in the chemical and pharmaceutical manufacturing sectors.

    Reasons to Buy this Report

    • High-Growth Market Opportunity : Capture market share in South Korea's fastest-growing hemostats segment with 9.6% CAGR, outpacing global trends and offering superior ROI potential for market entrants.
    • Demographic-Driven Demand : Leverage South Korea's aging population and rising chronic disease prevalence to forecast sustained surgical volume growth and long-term market expansion through 2030.
    • Premium Market Positioning : Access South Korea's advanced healthcare infrastructure and high-income patient base willing to adopt innovative hemostatic solutions with strong reimbursement support.
    • Competitive Intelligence : Understand South Korea-specific market dynamics, regulatory pathways, and healthcare provider preferences to develop targeted go-to-market strategies and competitive positioning.
    • Investment Decision Support : Make informed decisions on market entry, product development, and partnership strategies with comprehensive South Korea market sizing and five-year growth forecasts.

    Frequently asked questions

    What is the current size of South Korea's hemostats market?

    South Korea's hemostats market was valued at $13.0 million in 2025 and is projected to grow to $20.6 million by 2030.

    What is the growth rate of South Korea's hemostats market?

    South Korea's hemostats market is growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2030.

    What factors are driving growth in South Korea's hemostats market?

    South Korea's hemostats market growth is driven by an aging population, increased surgical volumes, advanced healthcare infrastructure, and rising adoption of minimally invasive procedures.

    Which hemostats products are most popular in South Korea?

    South Korea's hemostats market includes topical agents, mechanical devices, and combination therapies, with strong adoption driven by regulatory support for innovation.

    How does South Korea's hemostats market compare to global trends?

    South Korea's hemostats market CAGR of 9.6% significantly exceeds the global CAGR of 6.4%, reflecting stronger regional demand and healthcare investment.

    RESEARCH METHODOLOGY

    The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

    Secondary Research

    The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

    A breakdown of the primary respondents for the hemostats market is provided below:

    Hemostats Market

    Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

    Note 2: Others include sales, marketing, and product managers.

    Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The research methodology used to estimate the size of the hemostats market includes the following details.

    The market sizing was undertaken from the global side.

    Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry have been identified through extensive secondary research
    • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Hemostats Market Size: Top-down Approach

    Hemostats Market

    Data Triangulation

    After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

    Stakeholders

    • Senior Management
    • Finance Department
    • Procurement Department
    • Hospitals
    • Specialty Clinics
    • Trade Associations and Industry Bodies
    • Regulatory Bodies and Government Agencies
    • Business Research & Consulting Service Providers
    • Market Research & Consulting Firms
    • Venture Capitalists and Investors

    Report Objectives

    • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
    • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
    • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
    • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
    • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
    • To profile the key players in the hemostats market and comprehensively analyze their core competencies
    • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

     

    Get the Full Hemostats Market Report

    Full forecast, segment splits, and company analysis for all Hemostats Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status